Rewriting the rules of genetic medicine with tRNA therapeutics

Episode 214

0:00-30:48

Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic disease diagnoses, and asks whether a single engineered molecule could address it across many conditions at once. My guest today is Dr. Nerissa Kreher, Chief Medical Officer of Alltrna. Nerissa brings two decades of rare disease drug development experience, including CMO roles at Entrada Therapeutics, Tiburio Therapeutics, and AVROBIO, to the task of turning that platform thesis into an actual clinical program. We'll talk translation, trial design, and what it takes to bring the first engineered tRNA therapy into the clinic. 02:45 Meet Nerissa Kreher and Alltrna's tRNA platform 07:29 Gene-by-gene versus mutation-by-mutation drug development 12:08 What nonsense mutations are and why they matter 15:55 Phase 1 trial approval in Australia 19:49 What basket trials are and FDA receptiveness 27:27 Where Alltrna could be in five years Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Publisher

Beyond Biotech - the podcast from Labiotech

Published

September 11, 2026

Duration

31 min

Format

Podcast

Category

Issues · Tech News

Source

RSS feed

Host

Labiotech

BB

Beyond Biotech - the podcast from Labiotech

@beyondbiotechthepodcastfroml

#rewriting #geneticmedicine #trnatherapeutics

The Nile